

## Without Cirrhosis

**TABLE 139: SVR GENOTYPE 4 WITHOUT CIRRHOSIS TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	SOF12 + RBV12	1.28 (0.68 to 1.91)	18.15 (–22.15 to 43.64)
DCV24 + ASU24 + PR24		1.49 (1.12 to 2.12)	30.91 (8.97 to 51.12)
DCV24 + ASU24 + PR24	SOF24 + RBV24	1.15 (0.87 to 2.13)	12.36 (–12.13 to 51.00)
Random effect model	Residual deviance	3.781 vs. 4 data points	
	Deviance information criteria	17.861	
Fixed effect model	Residual deviance	3.818 vs. 4 data points	
	Deviance information criteria	17.935	

ASU = asunaprevir; Crl = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.